Table 2 Comparison of representative cisplatin-loaded nanocarriers with reported release profiles and biocompatibility.
From: Nanoarchaeosomes for synergistic photochemotherapy in triple-negative breast cancer
Carrier system | Release profile | Biocompatibility/safety | References |
|---|---|---|---|
SPI-77 (stealth liposomal cisplatin) | Extremely slow release (< 10% in vitro) | Minimal early-release toxicity; however, low bioavailability and limited efficacy in vivo | |
NC-6004 (Nanoplatin™) – PEG-P(Glu) polymeric micelle | Sustained release: ~ 20% at 24 h; ~ 48% at 96 h | Lower nephrotoxicity and neurotoxicity vs free cisplatin in animal models; | |
Gold-based layered NPs | Initial burst (~ 64% in 5 h) from two-layer NP; complete release in three-layer NP over 14 days | Biocompatible coatings (PC, HDL) used; specific toxicity data not detailed | |
Lipoplatin (liposomal cisplatin) | Release is triggered mainly after tumor cell uptake/fusion | Reduced systemic toxicity; advanced to human Phase I–III trials | |
Magnetoliposome (cisplatin + magnetic NPs) | Release via magnetic hyperthermia | Good in vitro/in vivo safety; improved survival in animal tumor models |
